MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease

Eur J Pharmacol. 1990 Jul 17;182(3):611-2. doi: 10.1016/0014-2999(90)90066-f.
No abstract available

MeSH terms

  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / pharmacology
  • Animals
  • Benserazide / pharmacology
  • Dizocilpine Maleate / pharmacology*
  • Dopamine Agents / pharmacology
  • Ergolines / pharmacology
  • Hydroxydopamines
  • Levodopa / pharmacology
  • Male
  • Medial Forebrain Bundle / physiology
  • Oxidopamine
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / metabolism*
  • Quinpirole
  • Rats
  • Rats, Inbred Strains
  • Receptors, Dopamine / drug effects*
  • Stereoisomerism
  • Stereotyped Behavior / drug effects

Substances

  • Dopamine Agents
  • Ergolines
  • Hydroxydopamines
  • Receptors, Dopamine
  • Quinpirole
  • Levodopa
  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
  • Dizocilpine Maleate
  • Benserazide
  • Oxidopamine